DHX9 and Ewing sarcoma: Thus, YK-4-279 treatment, as well as DHX9 downregulation, could represent a targetable opportunity for Ewing sarcoma [92,93,94], and the TK-216 derivative has recently concluded phase I/II trial as a monotherapy and in combination with vincristine in relapsed or refractory Ewing sarcoma patients [95].